Monday, December 12, 2022 12:00:53 PM
I cannot make sense of your statement. It is 100% disinformation. Anyone can verify that this is untrue.
Peer review does not work the way you suggest and nothing was hidden or withheld—it’s all there of course—go to the JAMA website or ask the editorial staff. PFS, pseudo, endpoints, OS, crossover, original protocol, were all included in the peer review. Furthermore, Liau and Ashkan are on video discussing all these aspects of the study over the years. Look at the documents attached to the manuscript at the JAMA site. It is all documented on the JAMA network website.
If you want to learn about the original trial protocol all those years ago, consult JAMA and the peer review documents that JAMA has published and made available worldwide. The links are included on the DCVax-L P3 peer review page at the JAMA Oncology website linked below.
Verify the documentation here:
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1673747242&Signature=YmWPqPQCKvIB7n9qa-xMmmbMuh1OHdpu-daeSIBdM1sIffk78vDecEbRLg6UMLjQySSjBRMj~9Vx1p~Ej1nZkkQgBWHAf7gUMhh62UbUZiRnB2wPtoWM-6lmiUBU6kS2IUwRwYbk0wYmHtP9txKnhi7xuNnY8m5w-maeKQOXwz~sBddSIvFxkwWnabPLZggvW9-KKAEoMihAjerpKD3UIzscEND5em5q0iYLo1f2bLN4Vbe7fx77zCTijhsp477oGyPNHKIhyAkRZsRI8BsZ8SyskxoMtJTmlQ6y95nSACd03PpABR84nWrJ1buJsOPetbh9FAMvOoioq7R-LRFLtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Contact JAMA: jamaonc@jamanetwork.org
Peer review does not work the way you suggest and nothing was hidden or withheld—it’s all there of course—go to the JAMA website or ask the editorial staff. PFS, pseudo, endpoints, OS, crossover, original protocol, were all included in the peer review. Furthermore, Liau and Ashkan are on video discussing all these aspects of the study over the years. Look at the documents attached to the manuscript at the JAMA site. It is all documented on the JAMA network website.
If you want to learn about the original trial protocol all those years ago, consult JAMA and the peer review documents that JAMA has published and made available worldwide. The links are included on the DCVax-L P3 peer review page at the JAMA Oncology website linked below.
Verify the documentation here:
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1673747242&Signature=YmWPqPQCKvIB7n9qa-xMmmbMuh1OHdpu-daeSIBdM1sIffk78vDecEbRLg6UMLjQySSjBRMj~9Vx1p~Ej1nZkkQgBWHAf7gUMhh62UbUZiRnB2wPtoWM-6lmiUBU6kS2IUwRwYbk0wYmHtP9txKnhi7xuNnY8m5w-maeKQOXwz~sBddSIvFxkwWnabPLZggvW9-KKAEoMihAjerpKD3UIzscEND5em5q0iYLo1f2bLN4Vbe7fx77zCTijhsp477oGyPNHKIhyAkRZsRI8BsZ8SyskxoMtJTmlQ6y95nSACd03PpABR84nWrJ1buJsOPetbh9FAMvOoioq7R-LRFLtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Contact JAMA: jamaonc@jamanetwork.org
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
